Eton Pharmaceuticals (ETON) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue reached $17.3M, up 117% year-over-year, driven by strong product sales, new launches, and licensing revenue.

• Achieved 17 consecutive quarters of sequential product revenue growth, supported by acquisitions of INCRELEX® and GALZIN®.

• Out-licensed INCRELEX® international rights, recognizing $1.8M in licensing revenue and $2.5M in deferred revenue.

• Net loss widened to $1.6M ($0.06/share) from $0.8M ($0.03/share) due to higher R&D and G&A expenses.

• Advanced late-stage pipeline with NDA submission for ET-600 and launch readiness for ET-400 in 2025.

Financial highlights

• Product sales reached $14.0M, a 76% increase from Q1 2024, with licensing revenue of $3.3M.

• Adjusted gross profit was $12.0M (69.5% margin), up from $5.2M (65.6%) last year; gross profit (GAAP) was $9.9M.

• Adjusted EBITDA was $3.7M, up from $0.5M in Q1 2024.

• Non-GAAP net income was $2.4M ($0.07/share); GAAP net loss was $1.6M ($0.06/share).

• Ended Q1 with $17.4M in cash and $2.1M in operating cash flow.

Outlook and guidance

• Expects to exit 2025 at an ~$80M annual revenue run rate, with full-year adjusted gross margin at ~70%.

• ET-400 launch expected in Q2 2025, pending FDA approval; ET-600 potential approval and launch in Q1 2026.

• No significant further SG&A investments planned for 2025; G&A spending expected to remain flat or decline.

• Management expects existing cash and product revenues to fund operations for at least the next 12 months.

• Ongoing focus on expanding rare disease portfolio and advancing late-stage product candidates.